- Home
- MAC vs PCVX Comparison
MAC vs PCVX Comparison
Compare MAC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | PCVX |
|---|---|---|
| Founded | 1964 | 2013 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.0B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAC | PCVX |
|---|---|---|
| Price | $24.80 | $58.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $20.50 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 3.8M | 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 11.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,013,983,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $15.94 | $29.10 |
| 52 Week High | $25.97 | $65.00 |
Technical Indicators
Market Signals| Indicator | MAC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 58.74 |
| Support Level | $17.84 | $42.30 |
| Resistance Level | $25.84 | $58.95 |
| Average True Range (ATR) | 0.60 | 2.71 |
| MACD | -0.14 | 0.55 |
| Stochastic Oscillator | 46.30 | 66.48 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.2 million square feet of gross leasable area and averaged $899 sales per square foot over the 12 months ended in March 2026.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.